Annual report
7459.TEDINET S100TRUJ
Period2023-04-01 → 2024-03-31
Filed2024-06-25
StandardJapan GAAP
ConsolidatedYes
Data checks24 of 24 passed
Key figures · 156
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥3.56T | 2023-04-01 → 2024-03-31 | Cons. | Net sales |
| Revenue | ¥3.36T | 2022-04-01 → 2023-03-31 | Cons. | Net sales |
| Revenue | ¥3.29T | 2021-04-01 → 2022-03-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥3.21T | 2020-04-01 → 2021-03-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥3.25T | 2019-04-01 → 2020-03-31d | Cons. | Net sales (5-year summary) |
| Operating income | ¥47.3bn | 2023-04-01 → 2024-03-31 | Cons. | Operating income |
| Operating income | ¥49.0bn | 2022-04-01 → 2023-03-31 | Cons. | Operating income |
| Ordinary income | ¥64.6bn | 2023-04-01 → 2024-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥65.1bn | 2022-04-01 → 2023-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥62.0bn | 2021-04-01 → 2022-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥53.0bn | 2020-04-01 → 2021-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥68.0bn | 2019-04-01 → 2020-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Profit before tax | ¥74.7bn | 2023-04-01 → 2024-03-31 | Cons. | Income before income taxes |
| Profit before tax | ¥70.1bn | 2022-04-01 → 2023-03-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥41.5bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥38.8bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥29.4bn | 2021-04-01 → 2022-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥23.9bn | 2020-04-01 → 2021-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥38.0bn | 2019-04-01 → 2020-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income | ¥51.8bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss |
| Net income | ¥48.3bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss |
| Total assets | ¥1.80T | at 2024-03-31 | Cons. | Assets |
| Total assets | ¥1.71T | at 2023-03-31 | Cons. | Assets |
| Total assets | ¥1.71T | at 2022-03-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥1.68T | at 2021-03-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥1.64T | at 2020-03-31d | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥1.06T | at 2024-03-31 | Cons. | Liabilities |
| Total liabilities | ¥1.02T | at 2023-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥736.6bn | at 2024-03-31 | Cons. | Net assets |
| Net assets / equity | ¥688.1bn | at 2023-03-31 | Cons. | Net assets |
| Net assets / equity | ¥649.1bn | at 2022-03-31d | Cons. | Net assets |
| Net assets / equity | ¥638.9bn | at 2021-03-31d | Cons. | Net assets (5-year summary) |
| Net assets / equity | ¥607.4bn | at 2020-03-31d | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥230.2bn | at 2024-03-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥195.0bn | at 2023-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥228.1bn | at 2024-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥193.6bn | at 2023-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥260.4bn | at 2022-03-31d | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥240.0bn | at 2021-03-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥224.5bn | at 2020-03-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Operating cash flow | ¥61.8bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥16.1bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥61.2bn | 2021-04-01 → 2022-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥34.4bn | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥56.9bn | 2019-04-01 → 2020-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | −¥7.8bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥39.5bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥24.3bn | 2021-04-01 → 2022-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥2.9bn | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥13.3bn | 2019-04-01 → 2020-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | −¥25.2bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥43.5bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥16.5bn | 2021-04-01 → 2022-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥16.0bn | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥49.1bn | 2019-04-01 → 2020-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥195.83 | 2023-04-01 → 2024-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥184.82 | 2022-04-01 → 2023-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥140.14 | 2021-04-01 → 2022-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥113.96 | 2020-04-01 → 2021-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥175.8 | 2019-04-01 → 2020-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥179.12 | 2022-04-01 → 2023-03-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥131.41 | 2021-04-01 → 2022-03-31d | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥106.8 | 2020-04-01 → 2021-03-31d | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥165.33 | 2019-04-01 → 2020-03-31d | Cons. | Diluted earnings per share (5-year summary) |
| Net assets per share | ¥2,858.57 | at 2024-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥2,673.62 | at 2023-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥2,525.72 | at 2022-03-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥2,490.98 | at 2021-03-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥2,382.88 | at 2020-03-31d | Cons. | Net assets per share (5-year summary) |
| Equity ratio | 33.4% | at 2024-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 32.8% | at 2023-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 31.0% | at 2022-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 31.1% | at 2021-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 30.4% | at 2020-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| ROE | 7.1% | 2023-04-01 → 2024-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 7.1% | 2022-04-01 → 2023-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 5.6% | 2021-04-01 → 2022-03-31d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 4.7% | 2020-04-01 → 2021-03-31d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 7.6% | 2019-04-01 → 2020-03-31d | Cons. | Rate of return on equity (5-year summary) |
| Employees | 13,075 | at 2024-03-31 | Cons. | Number of employees |
| Employees | 12,795 | at 2023-03-31 | Cons. | Number of employees |
| Employees | 12,801 | at 2022-03-31d | Cons. | Number of employees |
| Employees | 12,971 | at 2021-03-31d | Cons. | Number of employees |
| Employees | 13,599 | at 2020-03-31d | Cons. | Number of employees |
| Revenue | ¥30.3bn | 2023-04-01 → 2024-03-31 | Standalone | Operating revenue2 |
| Revenue | ¥33.0bn | 2022-04-01 → 2023-03-31 | Standalone | Operating revenue2 |
| Revenue | ¥26.6bn | 2021-04-01 → 2022-03-31d | Standalone | Operating revenue2 (5-year summary) |
| Revenue | ¥28.3bn | 2020-04-01 → 2021-03-31d | Standalone | Operating revenue2 (5-year summary) |
| Revenue | ¥69.8bn | 2019-04-01 → 2020-03-31d | Standalone | Operating revenue2 (5-year summary) |
| Operating income | ¥12.9bn | 2023-04-01 → 2024-03-31 | Standalone | Operating income |
| Operating income | ¥16.3bn | 2022-04-01 → 2023-03-31 | Standalone | Operating income |
| Ordinary income | ¥14.1bn | 2023-04-01 → 2024-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥18.2bn | 2022-04-01 → 2023-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥18.9bn | 2021-04-01 → 2022-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥19.0bn | 2020-04-01 → 2021-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥60.0bn | 2019-04-01 → 2020-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥23.4bn | 2023-04-01 → 2024-03-31 | Standalone | Income before income taxes |
| Profit before tax | ¥23.5bn | 2022-04-01 → 2023-03-31 | Standalone | Income before income taxes |
| Net income | ¥21.1bn | 2023-04-01 → 2024-03-31 | Standalone | Profit loss |
| Net income | ¥21.4bn | 2022-04-01 → 2023-03-31 | Standalone | Profit loss |
| Net income | ¥12.8bn | 2021-04-01 → 2022-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥20.7bn | 2020-04-01 → 2021-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥57.7bn | 2019-04-01 → 2020-03-31d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥368.2bn | at 2024-03-31 | Standalone | Assets |
| Total assets | ¥355.4bn | at 2023-03-31 | Standalone | Assets |
| Total assets | ¥373.6bn | at 2022-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥386.7bn | at 2021-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥368.5bn | at 2020-03-31d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥22.4bn | at 2024-03-31 | Standalone | Liabilities |
| Total liabilities | ¥21.8bn | at 2023-03-31 | Standalone | Liabilities |
| Net assets / equity | ¥345.7bn | at 2024-03-31 | Standalone | Net assets |
| Net assets / equity | ¥333.6bn | at 2023-03-31 | Standalone | Net assets |
| Net assets / equity | ¥321.0bn | at 2022-03-31d | Standalone | Net assets |
| Net assets / equity | ¥327.4bn | at 2021-03-31d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥312.0bn | at 2020-03-31d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥21.0bn | at 2024-03-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥18.6bn | at 2023-03-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥99.55 | 2023-04-01 → 2024-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥102.07 | 2022-04-01 → 2023-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥60.99 | 2021-04-01 → 2022-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥98.75 | 2020-04-01 → 2021-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥267.14 | 2019-04-01 → 2020-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥98.81 | 2022-04-01 → 2023-03-31 | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥56.93 | 2021-04-01 → 2022-03-31d | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥92.49 | 2020-04-01 → 2021-03-31d | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥251.47 | 2019-04-01 → 2020-03-31d | Standalone | Diluted earnings per share (5-year summary) |
| Dividend per share | ¥60 | 2023-04-01 → 2024-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥46 | 2022-04-01 → 2023-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥44 | 2021-04-01 → 2022-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥42 | 2020-04-01 → 2021-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥41 | 2019-04-01 → 2020-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥1,646.21 | at 2024-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,588.95 | at 2023-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,528.64 | at 2022-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,559.37 | at 2021-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,485.84 | at 2020-03-31d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 93.9% | at 2024-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 93.9% | at 2023-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 85.9% | at 2022-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 84.7% | at 2021-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 84.7% | at 2020-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 6.2% | 2023-04-01 → 2024-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 6.5% | 2022-04-01 → 2023-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 4.0% | 2021-04-01 → 2022-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 6.5% | 2020-04-01 → 2021-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 19.2% | 2019-04-01 → 2020-03-31d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 221,291,000 | at 2024-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 225,463,000 | at 2023-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 244,524,000 | at 2022-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 244,524,000 | at 2021-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 244,524,000 | at 2020-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 183 | at 2024-03-31 | Standalone | Number of employees |
| Employees | 173 | at 2023-03-31 | Standalone | Number of employees |
| Employees | 173 | at 2022-03-31d | Standalone | Number of employees |
| Employees | 169 | at 2021-03-31d | Standalone | Number of employees |
| Employees | 169 | at 2020-03-31d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 71
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | capex | 2023-04-01 → 2024-03-31 | ¥153m |
| Reconciling Itemsreconciling | depreciation | 2023-04-01 → 2024-03-31 | ¥114m |
| Reconciling Itemsreconciling | revenue | 2023-04-01 → 2024-03-31 | −¥3.1bn |
| Reconciling Itemsreconciling | revenue intersegment | 2023-04-01 → 2024-03-31 | −¥3.1bn |
| Reconciling Itemsreconciling | segment assets | at 2024-03-31 | ¥24.4bn |
| Reconciling Itemsreconciling | segment profit | 2023-04-01 → 2024-03-31 | −¥41m |
| Animal Health Products And Food Processing Raw Materials Wholesale And Related Businessreportable segment | capex | 2023-04-01 → 2024-03-31 | ¥472m |
| Animal Health Products And Food Processing Raw Materials Wholesale And Related Businessreportable segment | depreciation | 2023-04-01 → 2024-03-31 | ¥1.6bn |
| Animal Health Products And Food Processing Raw Materials Wholesale And Related Businessreportable segment | employees | at 2024-03-31 | 745 pure |
| Animal Health Products And Food Processing Raw Materials Wholesale And Related Businessreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥114.0bn |
| Animal Health Products And Food Processing Raw Materials Wholesale And Related Businessreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥114.0bn |
| Animal Health Products And Food Processing Raw Materials Wholesale And Related Businessreportable segment | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥2m |
| Animal Health Products And Food Processing Raw Materials Wholesale And Related Businessreportable segment | segment assets | at 2024-03-31 | ¥87.3bn |
| Animal Health Products And Food Processing Raw Materials Wholesale And Related Businessreportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥2.7bn |
| Cosmetics Daily Necessities And OTC Pharmaceutical Wholesale Businessreportable segment | capex | 2023-04-01 → 2024-03-31 | ¥1.6bn |
| Cosmetics Daily Necessities And OTC Pharmaceutical Wholesale Businessreportable segment | depreciation | 2023-04-01 → 2024-03-31 | ¥6.5bn |
| Cosmetics Daily Necessities And OTC Pharmaceutical Wholesale Businessreportable segment | employees | at 2024-03-31 | 2237 pure |
| Cosmetics Daily Necessities And OTC Pharmaceutical Wholesale Businessreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥1.15T |
| Cosmetics Daily Necessities And OTC Pharmaceutical Wholesale Businessreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥1.15T |
| Cosmetics Daily Necessities And OTC Pharmaceutical Wholesale Businessreportable segment | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥306m |
| Cosmetics Daily Necessities And OTC Pharmaceutical Wholesale Businessreportable segment | segment assets | at 2024-03-31 | ¥492.5bn |
| Cosmetics Daily Necessities And OTC Pharmaceutical Wholesale Businessreportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥27.2bn |
| Prescription Pharmaceutical Wholesale Businessreportable segment | capex | 2023-04-01 → 2024-03-31 | ¥18.2bn |
| Prescription Pharmaceutical Wholesale Businessreportable segment | depreciation | 2023-04-01 → 2024-03-31 | ¥8.5bn |
| Prescription Pharmaceutical Wholesale Businessreportable segment | employees | at 2024-03-31 | 9900 pure |
| Prescription Pharmaceutical Wholesale Businessreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥2.30T |
| Prescription Pharmaceutical Wholesale Businessreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥2.29T |
| Prescription Pharmaceutical Wholesale Businessreportable segment | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥2.7bn |
| Prescription Pharmaceutical Wholesale Businessreportable segment | segment assets | at 2024-03-31 | ¥1.19T |
| Prescription Pharmaceutical Wholesale Businessreportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥17.5bn |
| Total Of Reportable Segments And Otherssegment total | capex | 2023-04-01 → 2024-03-31 | ¥20.2bn |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2023-04-01 → 2024-03-31 | ¥16.6bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2023-04-01 → 2024-03-31 | ¥3.56T |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2023-04-01 → 2024-03-31 | ¥3.56T |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2023-04-01 → 2024-03-31 | ¥3.1bn |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2024-03-31 | ¥1.77T |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2023-04-01 → 2024-03-31 | ¥47.4bn |
| Reconciling Itemsreconciling | capex | 2022-04-01 → 2023-03-31 | ¥690m |
| Reconciling Itemsreconciling | depreciation | 2022-04-01 → 2023-03-31 | ¥110m |
| Reconciling Itemsreconciling | revenue | 2022-04-01 → 2023-03-31 | −¥7.8bn |
| Reconciling Itemsreconciling | revenue intersegment | 2022-04-01 → 2023-03-31 | −¥7.8bn |
| Reconciling Itemsreconciling | segment assets | at 2023-03-31 | ¥16.7bn |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2023-03-31 | ¥56m |
| Animal Health Products And Food Processing Raw Materials Wholesale And Related Businessreportable segment | capex | 2022-04-01 → 2023-03-31 | ¥121m |
| Animal Health Products And Food Processing Raw Materials Wholesale And Related Businessreportable segment | depreciation | 2022-04-01 → 2023-03-31 | ¥181m |
| Animal Health Products And Food Processing Raw Materials Wholesale And Related Businessreportable segment | revenue | 2022-04-01 → 2023-03-31 | ¥74.0bn |
| Animal Health Products And Food Processing Raw Materials Wholesale And Related Businessreportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥74.0bn |
| Animal Health Products And Food Processing Raw Materials Wholesale And Related Businessreportable segment | revenue intersegment | 2022-04-01 → 2023-03-31 | ¥2m |
| Animal Health Products And Food Processing Raw Materials Wholesale And Related Businessreportable segment | segment assets | at 2023-03-31 | ¥87.2bn |
| Animal Health Products And Food Processing Raw Materials Wholesale And Related Businessreportable segment | segment profit | 2022-04-01 → 2023-03-31 | ¥2.5bn |
| Cosmetics Daily Necessities And OTC Pharmaceutical Wholesale Businessreportable segment | capex | 2022-04-01 → 2023-03-31 | ¥10.2bn |
| Cosmetics Daily Necessities And OTC Pharmaceutical Wholesale Businessreportable segment | depreciation | 2022-04-01 → 2023-03-31 | ¥5.7bn |
| Cosmetics Daily Necessities And OTC Pharmaceutical Wholesale Businessreportable segment | revenue | 2022-04-01 → 2023-03-31 | ¥1.10T |
| Cosmetics Daily Necessities And OTC Pharmaceutical Wholesale Businessreportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥1.10T |
| Cosmetics Daily Necessities And OTC Pharmaceutical Wholesale Businessreportable segment | revenue intersegment | 2022-04-01 → 2023-03-31 | ¥321m |
| Cosmetics Daily Necessities And OTC Pharmaceutical Wholesale Businessreportable segment | segment assets | at 2023-03-31 | ¥472.9bn |
| Cosmetics Daily Necessities And OTC Pharmaceutical Wholesale Businessreportable segment | segment profit | 2022-04-01 → 2023-03-31 | ¥24.5bn |
| Prescription Pharmaceutical Wholesale Businessreportable segment | capex | 2022-04-01 → 2023-03-31 | ¥6.4bn |
| Prescription Pharmaceutical Wholesale Businessreportable segment | depreciation | 2022-04-01 → 2023-03-31 | ¥8.2bn |
| Prescription Pharmaceutical Wholesale Businessreportable segment | revenue | 2022-04-01 → 2023-03-31 | ¥2.19T |
| Prescription Pharmaceutical Wholesale Businessreportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥2.18T |
| Prescription Pharmaceutical Wholesale Businessreportable segment | revenue intersegment | 2022-04-01 → 2023-03-31 | ¥7.4bn |
| Prescription Pharmaceutical Wholesale Businessreportable segment | segment assets | at 2023-03-31 | ¥1.13T |
| Prescription Pharmaceutical Wholesale Businessreportable segment | segment profit | 2022-04-01 → 2023-03-31 | ¥21.9bn |
| Total Of Reportable Segments And Otherssegment total | capex | 2022-04-01 → 2023-03-31 | ¥16.7bn |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2022-04-01 → 2023-03-31 | ¥14.1bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-04-01 → 2023-03-31 | ¥3.37T |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-04-01 → 2023-03-31 | ¥3.36T |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2022-04-01 → 2023-03-31 | ¥7.8bn |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2023-03-31 | ¥1.69T |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-04-01 → 2023-03-31 | ¥48.9bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 2,052
| Item | Context | Value | Unit |
|---|---|---|---|
| Research and development expenses research and development activities | CurrentYearDuration_jpcrp030000-asr_E02632-000PrescriptionPharmaceuticalWholesaleBusinessReportableSegmentsMember | 225000000 | JPY |
| Research and development expenses research and development activities | CurrentYearDuration_jpcrp030000-asr_E02632-000CosmeticsDailyNecessitiesAndOTCPharmaceuticalWholesaleBusinessReportableSegmentsMember | 88000000 | JPY |
| Research and development expenses research and development activities | CurrentYearDuration_jpcrp030000-asr_E02632-000AnimalHealthProductsAndFoodProcessingRawMaterialsWholesaleAndRelatedBusinessReportableSegmentsMember | 677000000 | JPY |
| Capital expenditures overview of capital expenditures etc | CurrentYearDuration | 20380000000 | JPY |
| Number of issued shares as of fiscal year end issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | 221291342 | |
| Number of issued shares as of filing date issued shares total number of shares etc | FilingDateInstant_OrdinaryShareMember | 221291342 | |
| Number of issued shares as of fiscal year end issued shares total number of shares etc | FilingDateInstant | 221291342 | |
| Number of issued shares as of filing date issued shares total number of shares etc | FilingDateInstant | 221291342 | |
| Number of shares constituting one unit | CurrentYearInstant_OrdinaryShareMember | 100 | |
| Number of shareholders national and local governments | CurrentYearInstant_OrdinaryShareMember | － | |
| Number of shareholders financial institutions | CurrentYearInstant_OrdinaryShareMember | 32 | |
| Number of shareholders financial service providers | CurrentYearInstant_OrdinaryShareMember | 28 | |
| Number of shareholders other corporations | CurrentYearInstant_OrdinaryShareMember | 209 | |
| Number of shareholders foreign investors other than individuals | CurrentYearInstant_OrdinaryShareMember | 349 | |
| Number of shareholders foreign individual investors | CurrentYearInstant_OrdinaryShareMember | 9 | |
| Number of shareholders individuals and others | CurrentYearInstant_OrdinaryShareMember | 9194 | |
| Number of shareholders total | CurrentYearInstant_OrdinaryShareMember | 9821 | |
| Number of shares held number of units national and local governments | CurrentYearInstant_OrdinaryShareMember | － | |
| Number of shares held number of units financial institutions | CurrentYearInstant_OrdinaryShareMember | 483772 | |
| Number of shares held number of units financial service providers | CurrentYearInstant_OrdinaryShareMember | 44188 | |
| Number of shares held number of units other corporations | CurrentYearInstant_OrdinaryShareMember | 242461 | |
| Number of shares held number of units foreign investors other than individuals | CurrentYearInstant_OrdinaryShareMember | 871601 | |
| Number of shares held number of units foreign individual investors | CurrentYearInstant_OrdinaryShareMember | 43 | |
| Number of shares held number of units individuals and others | CurrentYearInstant_OrdinaryShareMember | 568934 | |
| Number of shares held number of units total | CurrentYearInstant_OrdinaryShareMember | 2210999 | |
| Number of shares held shares less than one unit | CurrentYearInstant_OrdinaryShareMember | 191442 | |
| Percentage of shareholdings national and local governments | CurrentYearInstant_OrdinaryShareMember | － | |
| Percentage of shareholdings financial institutions | CurrentYearInstant_OrdinaryShareMember | 0.2188 | |
| Percentage of shareholdings financial service providers | CurrentYearInstant_OrdinaryShareMember | 0.0200 | |
| Percentage of shareholdings other corporations | CurrentYearInstant_OrdinaryShareMember | 0.1097 | |
| Percentage of shareholdings foreigners other than individuals | CurrentYearInstant_OrdinaryShareMember | 0.3942 | |
| Percentage of shareholdings foreign individuals | CurrentYearInstant_OrdinaryShareMember | 0.0000 | |
| Percentage of shareholdings individuals and others | CurrentYearInstant_OrdinaryShareMember | 0.2573 | |
| Number of shares held | CurrentYearInstant_No1MajorShareholdersMember | 28564000 | |
| Shareholding ratio | CurrentYearInstant_No1MajorShareholdersMember | 0.1360 | |
| Number of shares held | CurrentYearInstant_No2MajorShareholdersMember | 11416000 | |
| Shareholding ratio | CurrentYearInstant_No2MajorShareholdersMember | 0.0544 | |
| Number of shares held | CurrentYearInstant_No3MajorShareholdersMember | 9042000 | |
| Shareholding ratio | CurrentYearInstant_No3MajorShareholdersMember | 0.0431 | |
| Number of shares held | CurrentYearInstant_No4MajorShareholdersMember | 5814000 | |
| Shareholding ratio | CurrentYearInstant_No4MajorShareholdersMember | 0.0277 | |
| Number of shares held | CurrentYearInstant_No5MajorShareholdersMember | 5773000 | |
| Shareholding ratio | CurrentYearInstant_No5MajorShareholdersMember | 0.0275 | |
| Number of shares held | CurrentYearInstant_No6MajorShareholdersMember | 5381000 | |
| Shareholding ratio | CurrentYearInstant_No6MajorShareholdersMember | 0.0256 | |
| Number of shares held | CurrentYearInstant_No7MajorShareholdersMember | 5074000 | |
| Shareholding ratio | CurrentYearInstant_No7MajorShareholdersMember | 0.0242 | |
| Number of shares held | CurrentYearInstant_No8MajorShareholdersMember | 4309000 | |
| Shareholding ratio | CurrentYearInstant_No8MajorShareholdersMember | 0.0205 | |
| Number of shares held | CurrentYearInstant_No9MajorShareholdersMember | 3493000 |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 24 of 24 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |